| [1] |
Arasaradnam RP, Brown S, Forbes A, et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition[J]. Gut, 2018, 67(8): 1380-1399.
|
| [2] |
Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea[J]. Clin Gastroenterol Hepatol, 2012, 10(9): 1009-1015.e3.
|
| [3] |
Valentin N, Camilleri M, Altayar O, et al. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis[Z]. Gut, 2016, 65(12): 1951-1959.
|
| [4] |
MartÍnez-augustin O, Medina FSD. Intestinal bile acid physiology and pathophysiology[J]. World Journal of Gastroenterology, 2008, 14(37): 5630.
|
| [5] |
Ticho AL, Malhotra P, Dudeja PK, et al. Intestinal absorption of bile acids in health and disease[J]. Compr Physiol, 2019, 10(1): 21-56.
|
| [6] |
Magnus Y, Bousaba J, Sannaa W, et al. Bile acid diarrhea is associated with increased intestinal permeability compared with irritable bowel syndrome-diarrhea[J]. Gastroenterology, 2022, 162(4): 1343-1345.
|
| [7] |
Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy[J]. Gut Liver, 2015, 9(3): 332-339.
|
| [8] |
Sadowski DC, Camilleri M, Chey WD, et al. Canadian association of gastroenterology clinical practice guideline on the management of bile acid diarrhea[J]. Journal of the Canadian Association of Gastroenterology, 2020, 3(1): e10-e27.
|
| [9] |
Merrick MV, Eastwood MA, Anderson JR, et al. Enterohepatic circulation in man of a gamma-emitting bile-acid conjugate, 23-selena-25-homotaurocholic acid (SeHCAT)[J]. J Nucl Med, 1982, 23(2): 126-130.
|
| [10] |
Black CJ, Ford AC. Biochemical tests for bile acid diarrhea: real-world studies required[J]. Am J Gastroenterol, 2021, 16(4): 833-834.
|
| [11] |
Brydon WG, Nyhlin H, Eastwood MA, et al. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea[J]. Eur J Gastroenterol Hepatol, 1996, 8(2): 117-123.
|
| [12] |
Camilleri M, Nadeau A, Tremaine W J, et al. Measurement of serum 7α-hydroxy-4-cholesten-3-one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry[J]. Neurogastroenterology & Motility, 2009, 21(7): 734-743.
|
| [13] |
GÄlman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis[J]. Gastroenterology, 2005, 129(5): 1445-1453.
|
| [14] |
Walters J. Making the diagnosis of bile acid diarrhea[J]. Am J Gastroenterol, 2020, 115(12): 1974-1975.
|
| [15] |
Mottacki N, SimrÉn M, Bajor A, et al. Review article: bile acid diarrhoea-pathogenesis, diagnosis and management[J]. Alimentary pharmacology & therapeutics, 2016, 43(8): 884-898.
|
| [16] |
Vijayvargiya P, Camilleri M, Shin A, et al. Methods for diagnosis of bile acid malabsorption in clinical practice[J]. Clinical Gastroenterology and Hepatology, 2013, 11(10): 1232-1239.
|
| [17] |
Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 426-434.
|
| [18] |
Chang C, Jiang J, Sun R, et al. Downregulation of serum and distal ileum fibroblast growth factor19 in bile acid diarrhoea patients[J]. Dig Dis Sci, 2022, 67(3): 872-879.
|
| [19] |
Pattni SS, Brydon WG, Dew T, et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention[J]. Aliment Pharmacol Ther, 2013, 38(8): 967-976.
|
| [20] |
Pattni SS, Brydon GW, Dew T, et al. Fibroblast growth factor 19 and 7α-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea[J]. Clinical and Translational Gastroenterology, 2012, 3(7): e18.
|
| [21] |
Borup C, Syversen C, Bouchelouche P, et al. Diagnosis of bile acid diarrhoea by fasting and postprandial measurements of fibroblast growth factor 19[J]. Eur J Gastroenterol Hepatol, 2015, 27(12): 1399-1402.
|
| [22] |
Borup C, Wildt S, Rumessen JJ, et al. Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea[J]. Aliment Pharmacol Ther, 2017, 45(11): 1433-1442.
|
| [23] |
Amplatz B, ZÖhrer E, Haas C, et al. Bile acid preparation and comprehensive analysis by high performance liquid chromatography-high-resolution mass spectrometry[J]. Clin Chim Acta, 2017, 464: 85-92.
|
| [24] |
Vijayvargiya P, Camilleri M, Chedid V, et al. Analysis of fecal primary bile acids detects increased stool weight and colonic transit in patients with chronic functional diarrhea[J]. Clinical Gastroenterology and Hepatology, 2019, 17(5): 922-929.
|
| [25] |
Vijayvargiya P, Camilleri M, Taylor A, et al. Combined fasting serum c4 and primary bile acids from a single stool sample to diagnose bile acid diarrhea[J]. Gastroenterology, 2020, 159(5): 1952-1954.
|
| [26] |
Vijayvargiya P, Gonzalez Izundegui D, Calderon G, et al. Fecal bile acid testing in assessing patients with chronic unexplained diarrhea: implications for healthcare utilization[J]. American Journal of Gastroenterology, 2020, 115(7): 1094-1102.
|
| [27] |
Kumar A, Al-hassi HO, Jain M, et al. A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients[J]. Scientific Reports, 2022, 12(1): 8313.
|
| [28] |
Vijayvargiya P, Camilleri M. Current practice in the diagnosis of bile acid diarrhea[J]. astroenterology 2019, 156(5): 1233-1238.
|
| [29] |
Covington JA, Westenbrink EW, Ouaret N, et al. Application of a novel tool for diagnosing bile acid diarrhoea[J]. Sensors (Basel), 2013, 13(9): 11899-11912.
|
| [30] |
Berti G, Rettura F, Lambiase C, et al. Empirical trial or diagnostic tests for bile acid diarrhea? That is the question![J]. Journal of Digestive Diseases, 2021, 22(9): 557-558.
|
| [31] |
Ferguson J, Walker K, Thomson AB. Limitations in the use of 14C-glycocholate breath and stool bile acid determinations in patients with chronic diarrhea[J]. 1986, 8(3 Pt 1): 258-262.
|
| [32] |
Orekoya O, Mclaughlin J, Leitao E, et al. Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy[J]. Clin Med (Lond), 2015, 15(3): 252-257.
|
| [33] |
Watson L, Lalji A, Bodla S, et al. Management of bile acid malabsorption using low-fat dietary interventions: a useful strategy applicable to some patients with diarrhoea-predominant irritable bowel syndrome?[J]. Clinical Medicine (London, England), 2015, 15(6): 536-540.
|
| [34] |
Koga T, Nishida T, Miwa H, et al. Effects of dietary butter fat on fecal bile acid excretion in patients with Crohn's disease on elemental diet[J]. Dig Dis Sci, 1984, 29(11): 994-999.
|
| [35] |
Walters JRF, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid[J]. Alimentary Pharmacology & Therapeutics, 2015, 41(1): 54-64.
|
| [36] |
Mroz MS, Keating N, Ward JB, et al. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo[J]. Gut, 2014, 63(5): 808-817.
|
| [37] |
Camilleri M, Vijayvargiya P. The role of bile acids in chronic diarrhea[J]. American Journal of Gastroenterology, 2020, 115(10): 1596-1603.
|
| [38] |
Lin S, Sanders DS, Gleeson JT, et al. Long-term outcomes in patients diagnosed with bile-acid diarrhoea[J]. Eur J Gastroenterol Hepatol, 2016, 28(2): 240-245.
|
| [39] |
Farrugia A, Arasaradnam R. Bile acid diarrhoea: pathophysiology, diagnosis and management[J]. Frontline Gastroenterology, 2021, 12(6): 500-507.
|
| [40] |
Wilcox C, Turner J, Green J. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption[J]. Alimentary Pharmacology & Therapeutics, 2014, 39(9): 923-939.
|